tert-butyl 4-(4-(oxazol-2-yl)phenyl)piperazine-1-carboxylate | 845616-98-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-butyl 4-(4-(oxazol-2-yl)phenyl)piperazine-1-carboxylate
• 英文别名: 4-(4-Oxazol-2-yl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester；tert-butyl 4-[4-(1,3-oxazol-2-yl)phenyl]piperazine-1-carboxylate
• CAS: 845616-98-0
• 化学式: C₁₈H₂₃N₃O₃
• 分子量: 329.399
• InChiKey: ZSZRCQWFVYEYCA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  58.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(4-(oxazol-2-yl)phenyl)piperazine-1-carboxylate 在 甲酸 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 2-(4-(4-((5-methylfuran-2-yl)methyl)piperazin-1-yl)phenyl)oxazole
  参考文献：
  名称：

  Discovery and Preliminary Structure–Activity Relationship of Arylpiperazines as Novel, Brain-Penetrant Antiprion Compounds

  摘要：

  Creutzfeldt-Jakob disease and kuru in humans, BSE in cattle, and scrapie in sheep are fatal neurodegenerative disorders. Such illnesses are caused by the conversion and accumulation of a misfolded pathogenic isoform (termed PrPSc) of a normally benign, host cellular protein, denoted PrPC. We employed high-throughput screening enzyme-linked immunosorbent assays to evaluate compounds for their ability to reduce the level of PrPSc in Rocky Mountain Laboratory prion-infected mouse neuroblastoma cells (ScN2a-cl3). Arylpiperazines were among the active compounds identified, but the initial hits suffered from low potency and poor drug-likeness. The best of those hits, such as 1, 7, 13, and 19, displayed moderate antiprion activity with EC50 values in the micromolar range. Key analogues were designed and synthesized on the basis of the structure-activity relationship, with analogues 41, 44, 46, and 47 found to have submicromolar potency. Analogues 41 and 44 were able to penetrate the blood-brain barrier and achieved excellent drug concentrations in the brains of mice after oral dosing. These compounds represent good starting points for further lead optimization in our pursuit of potential drug candidates for the treatment of prion diseases.

  DOI：

  10.1021/ml300472n
• 作为产物：
  描述：

  2-(4-溴苯基)-噁唑 、 N-Boc-哌嗪 生成 tert-butyl 4-(4-(oxazol-2-yl)phenyl)piperazine-1-carboxylate
  参考文献：
  名称：

  Benzoyl-piperazine derivatives

  摘要：

  本发明涉及以下式子的化合物，其中取代基在此处描述。这些化合物可以用于治疗基于甘氨酸摄取抑制剂的疾病，例如精神病、疼痛、记忆和学习中的神经退行性功能障碍、精神分裂症、痴呆症以及其他认知过程受损的疾病，例如注意力缺陷障碍或阿尔茨海默病。

  公开号：

  US07605163B2

文献信息

• Benzoyl-piperazine derivatives
  申请人：Jolidon J. Synese

  公开号：US20050209241A1

  公开（公告）日：2005-09-22

  The invention relates to compounds of formula wherein the substituents are described herein. The compounds may be used in the treatment of illnesses based on the glycine uptake inhibitor, such as psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.

  本发明涉及具有以下通式的化合物 其中取代基如本文所述。这些化合物可用于治疗基于抑制甘氨酸摄取的疾病，如精神疾病、疼痛、记忆和学习方面的神经退行性功能障碍、精神分裂症、痴呆症以及认知过程受损的其他疾病，例如注意力缺陷障碍或阿尔茨海默病。
• [EN] PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS<br/>[FR] PIPERAZINE AVEC GROUPE PHENYLE SUBSTITUE DE TYPE OR ET LEUR UTILISATION COMME INHIBITEURS DE GLYT1
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005014563A1

  公开（公告）日：2005-02-17

  The invention relates to compounds of formula (I) wherein the substituents are described in claim 1. The compounds may be used in the treatment of illnesses based on the glycine uptake inhibitor, such as psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.

  该发明涉及式（I）化合物，其中取代基如权利要求书中所述。这些化合物可用于治疗基于甘氨酸摄取抑制剂的疾病，如精神病、疼痛、记忆和学习中的神经退行性功能障碍、精神分裂症、痴呆症以及其他认知过程受损的疾病，如注意力缺陷障碍或阿尔茨海默病。
• BENZOYL-PIPERAZINE DERIVATIVES
  申请人：Jolidon Synese

  公开号：US20080119486A1

  公开（公告）日：2008-05-22

  The invention relates to compounds of formula wherein the substituents are described herein. The compounds may be used in the treatment of illnesses based on the glycine uptake inhibitor, such as psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.

  本发明涉及化合物的公式，其中取代基如下所述。该化合物可用于治疗基于甘氨酸摄取抑制剂的疾病，例如精神病、疼痛、记忆和学习中的神经退行性功能障碍、精神分裂症、痴呆和其他认知过程受损的疾病，例如注意力缺陷障碍或阿尔茨海默病。
• PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1656361B1

  公开（公告）日：2008-01-02
• US7319099B2
  申请人：——

  公开号：US7319099B2

  公开（公告）日：2008-01-15